v3.22.2.2
Segment, Geographic and Other Revenue Information - Revenues By Products - Footnotes (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Oct. 02, 2022
Oct. 03, 2021
Oct. 02, 2022
Oct. 03, 2021
Revenue from External Customer [Line Items]        
Revenues [1] $ 22,638 $ 24,035 $ 76,040 $ 57,450
PC1 [Member]        
Revenue from External Customer [Line Items]        
Revenues [2] 319 521 974 1,348
BioNTech [Member] | PC1 [Member]        
Revenue from External Customer [Line Items]        
Revenues $ 7 $ 187 $ 108 $ 274
[1] On December 31, 2021, we completed the sale of our Meridian subsidiary. Prior to its sale, Meridian was managed as part of the former Hospital therapeutic area (see footnote (b) below). Beginning in the fourth quarter of 2021, the financial results of Meridian are reflected as discontinued operations. See Note 1A.
[2] See Note 1A for information about our recent organizational changes. PC1 includes revenues from our contract manufacturing, including certain Comirnaty-related manufacturing activities performed on behalf of BioNTech ($7 million and $108 million for the third quarter and the first nine months of 2022, respectively, and $187 million and $274 million for the third quarter and the first nine months of 2021, respectively), and revenues from our active pharmaceutical ingredient sales operation, as well as revenues related to our manufacturing and supply agreements with former legacy Pfizer businesses/partnerships, including but not limited to, transitional manufacturing and supply agreements with Viatris following the spin-off of the Upjohn Business. Prior to the fourth quarter of 2021, PC1 was managed within our former Hospital product portfolio.